

DT01 Rec'd PCT/PTC 21 JAN 2005

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A diblock copolymer of formula A-B wherein
 polymer block A represents a linear pharmaceutically acceptable hydrophilic polymer with a molecular weight < 1,000, and
 polymer block B represents a polymer comprising at least two different monomers selected from glycolic acid, propiolactone, γ -butyrolactone, δ -valerolactone, γ -valerolactone, ϵ -caprolactone, trimethylene carbonate, p-dioxanone, tetramethylene carbonate, ϵ -lactone, 1,5-dioxepan-2-one [characterized in that] wherin the diblock copolymer is liquid at a temperature below 50°C.
2. (original) A diblock copolymer according to claim 1 wherein polymer block B represents a polymer comprising monomers selected from glycolic acid, propiolactone, γ -butyrolactone, δ -valerolactone, ϵ -caprolactone, trimethylene carbonate, p-dioxanone, tetramethylene carbonate, ϵ -lactone, 1,5-dioxepan-2-one or mixtures thereof.
3. (original) A diblock copolymer according to claim 1 wherein polymer block B represents a polymer comprising monomers of trimethylene carbonate and monomers selected from glycolic acid, propiolactone, γ -butyrolactone, δ -valerolactone, γ -valerolactone, ϵ -caprolactone, p-dioxanone, tetramethylene carbonate, ϵ -lactone, 1,5-dioxepan-2-one or mixtures thereof.

4. (original) A diblock copolymer according to claim 3 wherein polymer block B represents a polymer comprising monomers of trimethylene carbonate and monomers selected from glycolic acid, propiolactone, γ -butyrolactone, δ -valerolactone, ϵ -caprolactone, p-dioxanone, tetramethylene carbonate, ϵ -lactone, 1,5-dioxepan-2-one or mixtures thereof.
5. (original) A diblock copolymer according to claim 1 wherein polymer block B represents a polymer comprising monomers selected from propiolactone, γ -butyrolactone, δ -valerolactone, γ -valerolactone, ϵ -caprolactone, trimethylene carbonate, p-dioxanone, tetramethylene carbonate, ϵ -lactone, 1,5-dioxepan-2-one.
6. (original) A diblock copolymer according to claim 5 wherein polymer block B comprises two different monomers selected from propiolactone, γ -butyrolactone, δ -valerolactone, γ -valerolactone, ϵ -caprolactone, trimethylene carbonate, p-dioxanone, tetramethylene carbonate, ϵ -lactone, 1,5-dioxepan-2-one.
7. (original) A diblock copolymer according to claim 6 wherein polymer block B comprises monomers selected from ϵ -caprolactone and trimethylene carbonate.
8. (currently amended) A diblock copolymer according to [any one of claims] claim 1 [to 7] wherein polymer block A represents poly(C₁₋₂₀alkylene oxide) or a derivative thereof.
9. (original) A diblock copolymer according to claim 8

wherein the poly(C₁₋₂₀alkylene oxide) or the derivative thereof is poly(ethylene glycol) or a derivative thereof, in particular poly(ethylene glycol) monomethylether.

10. (original) A diblock copolymer according to claim 9 wherein the poly(ethylene glycol) or a derivative thereof has a molecular weight ranging from > 350 to ≤ 750 .
11. (original) A diblock copolymer according to claim 10 wherein the poly(ethylene glycol) or the derivative thereof has a molecular weight of 750.
12. (currently amended) A diblock copolymer according to [any one of claims] claim 1 [to 11] having a molecular weight ranging from 2,000 to 10,000.
13. (original) A diblock copolymer according to claim 12 having a molecular weight ranging from 2,000 to 8,000.
14. (original) A diblock copolymer according to claim 13 having a molecular weight ranging from 2,500 to 7,000.
15. (currently amended) A diblock copolymer according to [any one of claims] claim 1 [to 14] being a liquid at room temperature or at 37°C.
16. (currently amended) A composition comprising an active ingredient and one or more diblock copolymers of formula A-B according to [any one of claims] claim 1 [to 15 characterized in that] wherein the composition is liquid below 50°C.
17. (original) A composition according to claim 16 wherein the composition is non-aqueous.
18. (currently amended) A pharmaceutical dosage form comprising a therapeutically effective amount of a composition according to claim 16 [or 17].

19. (currently amended) A pharmaceutical dosage form according to claim 18 [characterized in that] wherein the dosage form is suitable for oral administration.
20. (currently amended) A pharmaceutical dosage form according to claim 18 [characterized in that] wherein the dosage form is suitable for parenteral administration.
21. (currently amended) A pharmaceutical dosage form according to [any one of claims] claim 18 [to 20] wherein the dosage form is an aqueous solution.
22. (currently amended) A process to prepare an aqueous solution comprising an active ingredient and one or more diblock copolymers of formula A-B according to [any one of claims] claim 1 [to 15 characterized by] comprising mixing the active ingredient with the one or more liquid copolymers, i.e. at a temperature below 50°C, followed by addition of water while stirring.
23. (currently amended) A process to prepare an aqueous solution comprising an active ingredient and one or more diblock copolymers of formula A-B according to [any one of claims] claim 1 [to 15 characterized by]
 - a) mixing the one or more copolymers with water at a temperature below 50°C, followed by
 - b) the addition of the active ingredient to the aqueous polymeric solution obtained under a) while stirring.
24. (cancelled)
25. (cancelled)
26. (currently amended) A pharmaceutical package suitable for commercial sale comprising a container, a pharmaceutical dosage form according to [any one of claims] claim 18 [to 21], and associated with said package written matter.